Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 6Breast 2Thoracic 1Gastrointestinal 1

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 260Paclitaxel 216Cyclophosphamide 173Docetaxel 146Letrozole 126Fulvestrant 121Capecitabine 121Doxorubicin 111Carboplatin 98Bevacizumab 90exemestane 88Anastrozole 85Tamoxifen 77Lapatinib 77pembrolizumab 68Albumin-Bound Paclitaxel 67pertuzumab 62palbociclib 60Taxes 59Gemcitabine 57eribulin 48130-nm albumin-bound paclitaxel 47Radiotherapy 46Everolimus 44Ado-Trastuzumab Emtansine 43Vinorelbine 39ixabepilone 32Epirubicin 30Cisplatin 30pegfilgrastim 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Megestrol Acetate × Breast × Clear all
NCT02269670 2022-04-05

Phase II Study of Everolimus Beyond Progression

Emory University

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Neoplasms

NCT01237327 2011-05-06

Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer

Pfizer

Phase 3 Completed
84 enrolled 12 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡